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SUPPLEMENTARY TABLE 1: Mean (SD) concentrations of metabolic biomarker measures from serum samples 








 Mean SD  Mean SD  r 
LIPOPROTEIN PARTICLES 
  
     
VLDL 
  
     
Total VLDL particle concentration (pmol/L) 82 36  117 46  0.300* 
Extremely large VLDL particles (pmol/L) 0.07 0.15  0.20 0.27  0.298* 
Very large VLDL particles (pmol/L) 0.37 0.85  1.23 1.50  0.327* 
Large VLDL particles (pmol/L) 3.5 4.8  8.5 7.6  0.316* 
Medium VLDL particles (pmol/L) 14.5 11.6  26.7 17.0  0.310* 
Small VLDL particles (pmol/L) 26.9 12.8  39.3 15.8  0.306* 
Very small VLDL particles (pmol/L) 36.1 10.3  40.4 11.8  0.162* 
IDL and LDL         
Total IDL+LDL particle concentration (pmol/L) 557 134  618 159  0.175* 
IDL particles (pmol/L) 99 24  105 29  0.114* 
Large LDL particles (pmol/L) 168 40  183 48  0.154* 
Medium LDL particles (pmol/L) 137 35  154 40  0.189* 
Small LDL particles (pmol/L) 153 39  175 47  0.204* 
HDL        
Total HDL particle concentration (nmol/L) 8.1 1.1  7.9 1.1  -0.114* 
Very large HDL particles (nmol/L) 0.34 0.21  0.18 0.16  -0.287* 
Large HDL particles (nmol/L) 1.16 0.50  0.77 0.45  -0.300* 
Medium HDL particles (nmol/L) 1.98 0.37  1.99 0.40  -0.040 
Small HDL particles (nmol/L) 4.62 0.45  4.94 0.46  0.218* 
PARTICLE SIZE        
VLDL particle size (nm) 36.1 1.4  37.7 1.8  0.301* 
LDL particle size (nm) 23.6 0.2  23.5 0.2  -0.167* 
HDL particle size (nm) 9.9 0.3  9.7 0.2  -0.319* 
TRIGLYCERIDES        
Serum triglycerides (mmol/L) 1.24 0.67  1.96 1.00  0.318* 
Extremely large VLDL triglycerides (mmol/L) 0.009 0.023  0.030 0.044  0.342* 
VLDL triglycerides (mmol/L) 0.75 0.60  1.39 0.90  0.319* 
IDL triglycerides (mmol/L) 0.135 0.037  0.153 0.044  0.178* 
LDL triglycerides (mmol/L) 0.201 0.075  0.246 0.117  0.199* 
HDL triglycerides (mmol/L) 0.152 0.038  0.169 0.043  0.143* 
CHOLESTEROL AND APOLIPOPROTEINS        
Serum cholesterol (mmol/L) 5.03 0.93  5.26 1.11  0.106* 
VLDL cholesterol (mmol/L) 0.64 0.27  0.86 0.33  0.268* 
Non-HDL cholesterol (mmol/L) 3.37 0.91  3.84 1.05  0.199* 
IDL cholesterol (mmol/L) 0.75 0.18  0.78 0.22  0.091* 
LDL cholesterol (mmol/L) 1.98 0.56  2.20 0.65  0.162* 
HDL cholesterol (mmol/L) 1.65 0.38  1.41 0.37  -0.248* 
HDL2 cholesterol (mmol/L) 1.13 0.38  0.88 0.37  -0.270* 
HDL3 cholesterol (mmol/L) 0.53 0.04  0.54 0.06  0.071 
Apolipoprotein B (g/L) 0.93 0.23  1.12 0.27  0.270* 
Apolipoprotein A-I (g/L) 1.71 0.23  1.63 0.24  -0.129* 
Apo B/Apo A-I 0.55 0.15  0.70 0.16  0.311* 
FATTY ACIDS        
Total FA concentration (mmol/L) 10.9 2.5  13.2 3.4  0.242* 
PUFA (%), relative to total fatty acids 38.2 3.8  33.8 4.5  -0.266* 
n-3 (%), relative to total fatty acids 3.86 1.01  3.55 0.85  -0.130* 
DHA (%), relative to total fatty acids 1.61 0.54  1.38 0.46  -0.135* 
n-6 (%), relative to total fatty acids 34.4 3.7  30.2 4.2  -0.251* 
Linoleic acid (%), relative to total fatty acids 29.0 3.7  25.0 3.8  -0.265* 
MUFA (%), relative to total fatty acids 28.0 3.4  31.1 3.9  0.257* 
SFA (%), relative to total fatty acids 33.8 2.2  35.1 2.4  0.113* 
n-6 /n-3  9.47 2.55  8.91 2.24  -0.022 
PUFA/SFA 1.14 0.16  0.97 0.17  -0.237* 
Double bonds per fatty acid 1.27 0.08  1.19 0.09  -0.209* 
AMINO ACIDS        
Isoleucine (mmol/L) 0.051 0.015  0.069 0.019  0.351* 
Leucine (mmol/L) 0.080 0.016  0.098 0.019  0.334* 
Valine (mmol/L) 0.199 0.038  0.230 0.044  0.270* 
Phenylalanine (mmol/L) 0.074 0.010  0.084 0.011  0.305* 
Tyrosine (mmol/L) 0.050 0.010  0.059 0.012  0.281* 
Alanine (mmol/L) 0.399 0.059  0.441 0.064  0.239* 
Glutamine (mmol/L) 0.595 0.068  0.581 0.078  -0.069 
Histidine (mmol/L) 0.065 0.009  0.066 0.009  0.071 
Glycine (mmol/L) 0.296 0.063  0.276 0.053  -0.086* 
GLYCOLYSIS-RELATED METABOLITES        
Glycerol (mmol/L) 0.098 0.037  0.114 0.039  0.138* 
Glucose (mmol/L) 4.64 0.67  5.12 1.22  0.231* 
Lactate (mmol/L) 1.42 0.35  1.62 0.44  0.140* 
Pyruvate (mmol/L) 0.077 0.022  0.091 0.027  0.196* 
KETONE BODIES        
Acetoacetate (mmol/L) 0.058 0.042  0.057 0.047  -0.013 
3-hydroxybuturate (mmol/L) 0.10 0.11  0.10 0.14  -0.024 
MISCELLANEOUS        
Citrate (mmol/L) 0.104 0.018  0.104 0.017  -0.001 
Acetate (mmol/L) 0.046 0.015  0.042 0.010  -0.103* 
Glycoprotein acetyls (mmol/L) 1.52 0.21  1.72 0.26  0.284* 
C-reactive protein (mg/L)2 1.70 2.70  3.15 4.17  0.253* 
Creatinine (mmol/L) 0.063 0.013  0.064 0.012  0.070 
Albumin (signal area) 0.105 0.009  0.105 0.009  0.040 
Alanine aminotransferase (U/L)2 14.8 9.7  31.7 36.4  0.336* 
Gamma-glutamyl transferase (U/L)2 27.6 27.7  62.5 70.8  0.356* 
HOMA-insulin resistance index2 1.9 4.0  9.7 87.5  0.389* 
The number of participants with both metabolite data and fatty liver measurements was n=2,002. Since some 
metabolic measures were not determined in a small number of study participants, for some measures, the 
concentrations are reported for n=1,939–2,002.  
Abbreviations: DHA, docosahexaenoic acid; HDL, high-density lipoprotein; HOMA, homeostatic model; IDL, 
intermediate-density lipoprotein; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acid; PUFA, 
polyunsaturated fatty acid; SFA, saturated fatty acid; VLDL, very-low-density lipoprotein.  
1Spearman correlation coefficients between absolute metabolite concentrations and the categorical fatty liver 
score (n=1,859–1,919). The fatty liver score was calculated by summarizing the values of the five widely 
accepted criteria for fatty liver: 1) the liver-to-kidney contrast (no=0 or clear contrast=1), 2) parenchymal 
brightness (normal=0, mild=1, intermediate=2 or severe brightness=3), 3) deep beam attenuation (clear=0, 
attenuated=1 or no visible=2 line of diaphragm) 4) bright vessel walls (normal=0, partly visible=1 or no visible=2 
vessel walls) and 5) visibility of the neck of the gallbladder (normal=0, partly visible=1, not visible=2). The final 
score included in values ranging from 0 to 9.  
2Measure not quantified by the NMR metabolomics platform.  
* Statistical significance at P<0.0007. 
 
SUPPLEMENTARY TABLE 2: Comparison of BMI and waist circumference as anthropometric covariates in the cross-sectional (metabolites in 2011 vs. fatty liver status in 
2011) and prospective (metabolites in 2001 vs. fatty liver status in 2011) associations. Odds ratios and their 95% confidence intervals are per 1-SD increment in the 
metabolic measures, and shown with adjustment for sex, age, BMI or waist circumference, alcohol intake, leisure-time physical activity and smoking.  
  
CROSS-SECTIONAL ASSOCIATIONS (2011) 
    
PROSPECTIVE ASSOCIATIONS (2001->2011) 
  
  BMI as covariate   WAIST as covariate   BMI as covariate   WAIST as covariate 
  OR 95%CI P   OR 95%CI  P   OR 95%CI  P   OR 95%CI P 
  Low High   Low High   Low High   Low High 
LIPOPROTEIN PARTICLES                                       
VLDL 
                   Total VLDL particle concentration  1.52 1.30 1.78 2E-7 
 
1.54 1.32 1.81 9E-8 
 
1.38 1.16 1.64 3E-4 
 
1.45 1.22 1.72 2E-5 
Extremely large VLDL particles  1.83 1.50 2.22 1E-9 
 
1.82 1.50 2.22 2E-9 
 
1.42 1.19 1.69 8E-5 
 
1.46 1.23 1.74 2E-5 
Very large VLDL particles  1.67 1.35 2.08 4E-6 
 
1.68 1.35 2.09 3E-6 
 
1.51 1.20 1.89 3E4 
 
1.60 1.28 2.01 4E-5 
Large VLDL particles  1.93 1.51 2.46 2E-7 
 
1.98 1.54 2.54 8E-8 1.41 1.13 1.75 0.002 
 
1.51 1.21 1.89 3E-4 
Medium VLDL particles  1.70 1.45 1.99 4E-11 
 
1.74 1.48 2.03 8E-12 
 
1.45 1.21 1.72 3E-5 
 
1.53 1.29 1.82 1E-6 
Small VLDL particles  1.53 1.29 1.81 7E-7 
 
1.55 1.31 1.84 3E-7 
 
1.39 1.16 1.67 4E-4 
 
1.48 1.23 1.77 2E-5 
Very small VLDL particles  1.05 0.92 1.20 0.47 
 
1.06 0.93 1.21 0.41 
 
1.08 0.93 1.25 0.29 
 
1.10 0.95 1.28 0.19 
IDL and LDL     
 
    
 
    
 
    
Total IDL+LDL particle concentration  1.13 0.99 1.28 0.07 
 
1.14 1.00 1.30 0.05 
 
1.13 0.97 1.31 0.12 
 
1.16 1.00 1.35 0.05 
IDL particles  1.01 0.89 1.14 0.92 
 
1.01 0.89 1.15 0.82 
 
1.04 0.89 1.20 0.65 
 
1.05 0.91 1.22 0.51 
Large LDL particles  1.08 0.95 1.22 0.27 
 
1.09 0.96 1.24 0.19 
 
1.08 0.93 1.25 0.34 
 
1.10 0.95 1.28 0.20 
Medium LDL particles  1.15 1.01 1.31 0.03 
 
1.17 1.02 1.33 0.02 
 
1.14 0.98 1.32 0.10 
 
1.17 1.01 1.36 0.04 
Small LDL particles  1.22 1.07 1.40 0.002 
 
1.24 1.09 1.41 0.001 
 
1.23 1.06 1.43 0.007 
 
1.28 1.10 1.48 0.001 
HDL     
 
    
 
    
 
    
Total HDL particle concentration  1.05 0.91 1.21 0.51 
 
1.10 0.95 1.27 0.18 
 
1.05 0.89 1.24 0.54 
 
1.04 0.88 1.22 0.64 
Very large HDL particles  0.75 0.66 0.85 6E-6 
 
0.74 0.65 0.84 3E-6 
 
0.92 0.80 1.06 0.26 
 
0.91 0.80 1.05 0.19 
Large HDL particles  0.65 0.54 0.79 8E-6 
 
0.67 0.55 0.80 3E-5 0.67 0.54 0.83 3E-4 
 
0.64 0.51 0.79 3E-5 
Medium HDL particles  1.18 1.03 1.35 0.02 
 
1.23 1.07 1.41 0.003 
 
1.13 0.97 1.33 0.13 
 
1.12 0.95 1.31 0.17 
Small HDL particles  1.50 1.30 1.73 2E-8 
 
1.57 1.37 1.81 3E-10 1.34 1.15 1.56 1E-04 
 
1.37 1.18 1.58 3E-5 
PARTICLE SIZE     
 
    
 
    
 
    
VLDL particle size 1.74 1.51 2.00 4E-15 
 
1.77 1.54 2.03 5E-16 
 
1.58 1.35 1.84 1E-08 
 
1.65 1.42 1.92 1E-10 
LDL particle size  0.72 0.63 0.82 1E-6 
 
0.71 0.62 0.81 3E-7 0.71 0.60 0.83 2E-05 
 
0.68 0.58 0.79 1E-6 
HDL particle size 0.57 0.47 0.69 8E-9 
 
0.57 0.47 0.69 8E-9  0.67 0.55 0.82 1E-04 
 
0.64 0.52 0.78 1E-5 
TRIGLYCERIDES     
 
    
 
    
 
    
Serum triglycerides  1.69 1.46 1.97 7E-12 
 
1.72 1.48 2.00 2E-12 
 
1.51 1.28 1.79 1E-6 
 
1.60 1.35 1.89 4E-8 
Extremely large VLDL triglycerides  2.28 1.72 3.02 1E-8 
 
2.23 1.68 2.96 3E-8 
 
1.68 1.36 2.07 2E-6 
 
1.76 1.42 2.18 2E-7 
VLDL triglycerides 1.78 1.51 2.10 5E-12 
 
1.81 1.54 2.14 1E-12 1.55 1.29 1.85 2E-6 
 
1.64 1.37 1.96 5E-8 
IDL triglycerides  1.15 1.01 1.31 0.03 
 
1.16 1.02 1.32 0.03 
 
1.09 0.95 1.27 0.23 
 
1.11 0.96 1.28 0.17 
LDL triglycerides  1.24 1.08 1.43 0.003 
 
1.23 1.06 1.41 0.005 
 
1.31 1.11 1.55 0.002 
 
1.36 1.15 1.61 4E-4 
HDL triglycerides  1.22 1.07 1.38 0.002 
 
1.24 1.10 1.41 0.0007 
 
1.04 0.90 1.20 0.61 
 
1.04 0.90 1.20 0.58 
CHOLESTEROL AND APOLIPOPROTEINS     
 
    
 
    
 
    
Serum cholesterol  1.06 0.93 1.20 0.41 
 
1.08 0.95 1.23 0.24 
 
1.05 0.90 1.22 0.55 
 
1.07 0.92 1.24 0.37 
VLDL cholesterol  1.33 1.14 1.56 3E-4 
 
1.35 1.16 1.58 2E-4 
 
1.25 1.06 1.49 0.009 
 
1.31 1.11 1.56 0.002 
Non-HDL cholesterol 1.10 0.95 1.27 0.19 
 
1.12 0.97 1.29 0.13 
 
1.07 0.91 1.25 0.43 
 
1.11 0.94 1.30 0.21 
IDL cholesterol  0.97 0.86 1.10 0.68 
 
0.98 0.87 1.12 0.80 
 
1.00 0.86 1.16 0.98 
 
1.02 0.88 1.18 0.82 
LDL cholesterol  1.08 0.95 1.23 0.23 
 
1.10 0.96 1.25 0.17 
 
1.07 0.92 1.24 0.39 
 
1.10 0.95 1.28 0.21 
HDL cholesterol  0.74 0.64 0.87 2E-4 
 
0.76 0.65 0.89 0.0007 
 
0.82 0.69 0.98 0.03 
 
0.80 0.68 0.96 0.01 
HDL2 cholesterol  0.70 0.60 0.82 9E-6 
 
0.72 0.61 0.84 4E-5 
 
0.76 0.64 0.92 0.004 
 
0.74 0.62 0.89 0.001 
HDL3 cholesterol  1.05 0.92 1.19 0.49 
 
1.07 0.94 1.22 0.28 
 
1.22 1.06 1.41 0.006 
 
1.27 1.10 1.46 0.001 
Apolipoprotein B  1.38 1.19 1.61 2E-5 
 
1.40 1.20 1.62 2E-5 
 
1.29 1.09 1.52 0.003 
 
1.35 1.15 1.60 3E-4 
Apolipoprotein A-I  0.90 0.78 1.04 0.15 
 
0.93 0.81 1.07 0.33 
 
0.99 0.84 1.16 0.88 
 
0.99 0.85 1.16 0.93 
Apo B/Apo A-I 1.56 1.32 1.85 2E-7 
 
1.54 1.30 1.83 4E-7 
 
1.32 1.10 1.59 0.003 
 
1.39 1.16 1.67 4E-4 
FATTY ACIDS     
 
    
 
    
 
    
Total FA concentration  1.56 1.36 1.79 3E-10 
 
1.58 1.38 1.82 7E-11 
 
1.38 1.19 1.60 3E-05 
 
1.43 1.24 1.66 2E-6 
PUFA (%), relative to total fatty acids 0.45 0.39 0.53 1E-24 
 
0.45 0.39 0.52 8E-25 
 
0.55 0.47 0.64 2E-14 
 
0.53 0.46 0.62 4E-16 
n-3 (%), relative to total fatty acids 0.82 0.71 0.95 0.007 
 
0.83 0.72 0.96 0.01 
 
0.85 0.73 0.99 0.04 
 
0.85 0.73 0.99 0.04 
DHA (%), relative to total fatty acids 0.78 0.68 0.90 6E-4 
 
0.78 0.68 0.90 0.0007 
 
0.82 0.71 0.96 0.01 
 
0.81 0.70 0.95 0.008 
n-6 (%), relative to total fatty acids 0.47 0.40 0.54 2E-23 
 
0.46 0.40 0.54 7E-24 0.56 0.48 0.66 3E-13 
 
0.55 0.47 0.64 7E-15 
Linoleic acid (%), relative to total fatty acids 0.46 0.39 0.54 2E-22 
 
0.45 0.39 0.53 1E-22  0.56 0.48 0.66 7E-13 
 
0.54 0.46 0.63 2E-14 
MUFA (%), relative to total fatty acids 1.70 1.47 1.97 8E-13 
 
1.72 1.49 1.99 2E-13  1.59 1.36 1.86 4E-9 
 
1.63 1.40 1.90 4E-10 
SFA (%), relative to total fatty acids 1.73 1.50 1.99 2E-14 
 
1.71 1.49 1.97 5E-14  1.45 1.25 1.68 1E-6 
 
1.48 1.28 1.72 2E-7 
n-6 /n-3  0.80 0.69 0.92 0.002 
 
0.79 0.69 0.91 0.001 
 
0.91 0.79 1.06 0.23 
 
0.90 0.77 1.04 0.16 
PUFA/SFA 0.43 0.37 0.51 5E-25 
 
0.43 0.37 0.51 6E-25 
 
0.56 0.48 0.65 6E-13 
 
0.54 0.46 0.63 2E-14 
Double bonds per fatty acid 0.51 0.44 0.59 6E-19 
 
0.51 0.44 0.59 1E-18 
 
0.59 0.50 0.69 3E-11 
 
0.57 0.49 0.67 3E-12 
     
 
    
 
    
 
    
AMINO ACIDS 
Isoleucine  1.86 1.58 2.19 2E-13  1.88 1.59 2.21 8E-14 
 
1.67 1.40 1.99 8E-9 
 
1.75 1.47 2.08 2E-10 
Leucine  2.09 1.76 2.48 3E-17 
 
2.09 1.76 2.49 3E-17 
 
1.75 1.47 2.10 6E-10 
 
1.84 1.54 2.19 9E-12 
Valine  1.44 1.25 1.67 7E-7 1.44 1.25 1.66 7E-7 
 
1.34 1.15 1.57 2E4 
 
1.37 1.17 1.60 7E-5 
Phenylalanine 1.69 1.46 1.97 7E-12  1.71 1.47 1.99 3E-12 
 
1.17 1.00 1.37 0.06 
 
1.23 1.05 1.44 0.01 
Tyrosine  1.58 1.37 1.81 3E-10  1.60 1.39 1.84 6E-11 
 
1.26 1.08 1.47 0.003 
 
1.29 1.11 1.51 0.001 
Alanine  1.61 1.41 1.84 2E-12  1.66 1.45 1.90 1E-13 
 
1.31 1.14 1.52 2E-4 
 
1.36 1.18 1.56 2E-5 
Glutamine  0.78 0.68 0.90 0.0007 
 
0.78 0.68 0.90 0.0008 
 
0.90 0.77 1.07 0.23 
 
0.90 0.76 1.06 0.19 
Histidine  1.09 0.96 1.25 0.18 
 
1.12 0.98 1.28 0.09 
 
0.94 0.81 1.10 0.47 
 
0.95 0.82 1.11 0.53 
Glycine  0.86 0.74 1.01 0.06 
 
0.86 0.74 1.01 0.06 
 
0.94 0.80 1.10 0.45 
 
0.94 0.80 1.10 0.43 
GLYCOLYSIS-RELATED METABOLITES     
 
    
 
    
 
    
Glycerol 1.44 1.23 1.68 4E-6 
 
1.47 1.26 1.71 1E-6 
 
1.24 1.05 1.47 0.01 
 
1.25 1.06 1.48 0.007 
Glucose 1.29 1.13 1.47 2E-4 
 
1.33 1.17 1.52 2E-5 
 
1.10 0.96 1.27 0.18 
 
1.11 0.97 1.29 0.13 
Lactate 1.46 1.27 1.67 7E-8 
 
1.46 1.27 1.67 5E-8 
 
1.06 0.92 1.22 0.44 
 
1.06 0.92 1.23 0.41 
Pyruvate 1.45 1.26 1.66 1E-7 
 
1.52 1.32 1.74 2E-9 
 
1.23 1.07 1.43 0.004 
 
1.28 1.11 1.48 0.0008 
KETONE BODIES     
 
    
 
    
 
    
Acetoacetate 0.88 0.76 1.01 0.07 
 
0.87 0.76 1.01 0.07 
 
1.02 0.88 1.19 0.75 
 
1.02 0.88 1.19 0.77 
3-hydroxybuturate 1.00 0.88 1.15 0.96 
 
0.97 0.85 1.11 0.65 
 
0.93 0.81 1.08 0.37 
 
0.97 0.83 1.12 0.64 
MISCELLANEOUS     
 
    
 
    
 
    
Citrate 1.12 0.97 1.28 0.13 
 
1.09 0.95 1.26 0.22 
 
0.97 0.83 1.13 0.67 
 
0.99 0.85 1.15 0.89 
Acetate 0.68 0.58 0.80 2E-6 
 
0.70 0.60 0.82 1E-5 
 
0.99 0.86 1.13 0.85 
 
0.96 0.84 1.10 0.59 
Glycoprotein acetyls 1.53 1.33 1.75 9E-10 
 
1.56 1.36 1.79 1E-10 
 
1.34 1.16 1.55 6E-5 
 
1.42 1.23 1.64 1E-6 
C-reactive protein 1.38 1.18 1.62 6E-5 
 
1.37 1.17 1.60 1E-4 
 
1.01 0.86 1.19 0.91 
 
1.04 0.89 1.23 0.62 
Creatinine 0.91 0.78 1.06 0.23 
 
0.89 0.77 1.04 0.15 
 
1.07 0.90 1.27 0.42 
 
1.04 0.88 1.23 0.65 
Albumin (signal area) 1.01 0.88 1.15 0.93 
 
1.06 0.93 1.22 0.37 
 
0.99 0.85 1.16 0.90 
 
1.00 0.86 1.17 0.97 
Alanine aminotransferase 2.47 2.09 2.93 5E-26 
 
2.49 2.11 2.95 1E-26 
 
1.43 1.23 1.67 6E-6 
 
1.48 1.27 1.73 4E-7 
Gamma-glutamyl transferase 2.07 1.78 2.42 2E-20 
 
2.08 1.79 2.43 5E-21 
 
1.59 1.35 1.88 2E-8 
 
1.67 1.42 1.96 7E-10 
HOMA-insulin resistance index 2.25 1.86 2.72 5E-17   2.26 1.87 2.72 2E-17   1.53 1.28 1.82 2E-6   1.63 1.37 1.94 4E-8 
Cross-sectional associations included in 1,939–2,002 individuals of whom 339–372 had diagnosed fatty liver in 2011. Prospective associations included in 1,516–1,575 individuals with 
metabolite data at the 2001-baseline, of whom 263–275 had fatty liver diagnosed in 2011. 
Prior to prospective analyses, individuals with suspected fatty liver in 2001 were excluded (alanine aminotransferase > 30 U/L). 
P-values in the exponential format denote metabolite associations that were statistically significant associations when accounting for Bonferroni-correction (P<0.0007). 
DHA, docosahexaenoic acid; HDL, high-density lipoprotein; HOMA-IR, homeostatic model-based insulin resistance index; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; 
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SUPPLEMENTARY FIGURE 1: Prospective associations of metabolic measures with 4-year risk 
for fatty liver (n=1,455–1,509 with metabolite data at the 2007-survey, of whom 207-212 had 
fatty liver diagnosed in 2011). Odds ratios (95% confidence intervals) are per 1-SD increment in 
the metabolic measures, and shown with adjustment for sex and age (blue), and additionally for 
baseline waist, alcohol intake, leisure-time physical activity and smoking (red). P-values listed in 
exponential format denote metabolite associations that were statistically significant 
associations when accounting for Bonferroni-correction (P<0.0007). Individuals with suspected 
fatty liver in 2007 (alanine aminotransferase > 30 U/L) were excluded from analyses.  
 
